Liquid-handling Roboter

液体处理机器人

• 批准号: 434271776
• 金额: --
• 依托单位: Universität zu Köln
• 依托单位国家: 德国
• 项目类别: Major Research Instrumentation
• 财政年份: 2019
• 资助国家: 德国
• 起止时间: 2018-12-31 至 无数据
• 项目状态: 未结题
• 来源: https://gepris.dfg.de/gepris/projekt/434271776?language=en
• 关键词: Liquid; handling; Roboter

Our work focuses on the analysis of B cell and antibody responses against clinically relevant pathogens such as HIV, HCV, or Ebola. We use our findings to develop antibody-based therapies and inform on novel vaccination strategies. In the last years, we have been able to identify highly potent antibodies that we also successfully tested in clinical trials. Our advanced single cell cloning methods critically rely on multicolor flow cytometry with bulk and single cell sorting applications. With these methods, we are able to isolate specific cell populations, such as naive or memory B cells, by labeling them with fluorescent dyes. Several labels are necessary to yield a pure B cell sub-population, which in turn requires an instrument with several excitation lasers, emission filters, and detectors. Since we work with infectious materials (BSL2), the instrument further needs to be operated within a safety cabinet. We already have all necessary permissions to conduct these kind of experiments, but are currently working on a rental instrument with a fixed expiration of the rental contract. Thus, we apply for funding for a flow cytometer with single cell sorting function in order to continue our intensive research on novel vaccination- and therapy strategies.We have optimized our single cell cloning methods in the past and currently reached a capacity limit due to technical and structural limitations, which hampers the realization of our ongoing and planed projects. Based on our experience in manual single cell cloning, we plan to build an automated single cell platform for antibody analysis and screening. With this, we aim to (i) increase the sample throughput, (ii) reduce overall costs by volume reduction, and (iii) ensure a high quality among all analyses independent of any experimenter. To this end, we apply for funding for a liquid handling robot, that is able to process several sample in a 384-well plate format in parallel. The automation will allow us to identify therapeutically applicable antibodies against established and emerging infectious diseases in a shorter time frame and thereby strengthen our national and international position as an antibody analysis center of excellence.

我们的工作重点是分析B细胞和抗体对临床相关病原体的反应，如艾滋病毒、丙型肝炎病毒或埃博拉病毒。我们利用我们的发现来开发基于抗体的疗法，并告知新的疫苗接种策略。在过去的几年里，我们已经能够识别出高度有效的抗体，我们也成功地在临床试验中进行了测试。我们先进的单细胞克隆方法在很大程度上依赖于具有批量和单细胞分选应用的多色流式细胞术。使用这些方法，我们能够通过用荧光染料标记来分离特定的细胞群，例如幼稚或记忆B细胞。为了产生纯B细胞亚群，需要几个标记，这反过来又需要一个带有几个激发激光器、发射滤光器和探测器的仪器。由于我们使用的是传染性材料(BSL2)，仪器还需要在安全柜中操作。我们已经拥有进行这类实验的所有必要许可，但目前正在研究一种租赁合同固定到期的租赁工具。因此，我们申请了一台具有单细胞分选功能的流式细胞仪，以继续我们对新的疫苗接种和治疗策略的深入研究。我们过去优化了我们的单细胞克隆方法，但由于技术和结构的限制，目前达到了容量限制，这阻碍了我们正在进行的和计划的项目的实现。基于我们在人工单细胞克隆方面的经验，我们计划建立一个用于抗体分析和筛选的自动化单细胞平台。通过这样做，我们的目标是(I)增加样品吞吐量，(Ii)通过减少体积来降低总体成本，以及(Iii)确保独立于任何实验人员的所有分析的高质量。为此，我们申请了一种液体搬运机器人的资金，它能够并行处理384孔板格式的几个样品。自动化将使我们能够在更短的时间内识别针对既有和新出现的传染病的可用于治疗的抗体，从而加强我们作为抗体分析中心的国内和国际地位。